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Introduction: Following surgery, the formation of heterotopic ossiﬁcation (HTO) can limit mobility and
impair quality of life. Radiotherapy has been proven to provide efﬁcacious prophylaxis against HTO, espe-
cially in high-risk settings.
Purpose: The current review aims to determine the factors inﬂuencing HTO formation in patients receiv-
ing prophylactic radiotherapy.
Methods: A systematic search of the literature was conducted on Ovid Medline, Embase and the Cochrane
Central Register of Controlled Trials. Studies were included if they reported the percentage of sites devel-
oping heterotopic ossiﬁcation after receiving a speciﬁed dose of prophylactic radiotherapy. Weighted lin-
ear regression analysis was conducted for continuous or categorical predictors.
Results: Extracted from 61 articles, a total of 5464 treatment sites were included, spanning 85 separate
study arms. Most sites were from the hip (97.7%), from United States patients (55.2%), and had radiation
prescribed postoperatively (61.6%) at a dose of 700 cGy (61.0%). After adjusting for radiation site, there
was no statistically signiﬁcant relationship between the percentage of sites developing HTO and radiation
dose (p = 0.1) or whether radiation was administered preoperatively or postoperatively (p = 0.1). Sites
with previous HTO formation were more likely to develop recurrent HTO than those without previous
HTO formation (p = 0.04). There was a statistically signiﬁcant negative relationship between the HTO
development and the cohort mean year of treatment (p = 0.007).
Conclusion: Decreases in rates of HTO over time in this patient population may be a function of more efﬁ-
cacious surgical regimens and prophylactic radiotherapy.
 2014 Elsevier Ireland Ltd. Radiotherapy and Oncology 113 (2014) 10–17 This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Heterotopic ossiﬁcation (HTO) is characterized by the formation
of ectopic bone within muscles, connective tissue, or nerves [1].
Although HTO can be an indolent condition, more severe cases
can be painful, inﬂamed, or impair a patient’s mobility [2]. HTO for-
mation has been shown to be induced by bone morphogenic pro-
tein 2 (BMP2) in several primary cancer sites [3]. Currently, it is
postulated that BMP2 interacts with the Wnt/b-catenin signaling
pathway in osteoblasts to lead to osteoplastic differentiation and
bone formation [4]. Heterotopic ossiﬁcation may be caused by sur-
gical intervention or trauma. Common risk factors for heterotopic
ossiﬁcation include diffuse idiopathic skeletal hyperostosis,
ankylosing spondylitis, osteoarthritis, and previous heterotopic
ossiﬁcation formation.Literature examining HTO incidence following surgery has
nearly exclusively focused on hip operations. For example, follow-
ing total hip arthroplasty, total incidence of HTO approximates 60%
without prophylaxis [5]. In the hip setting, a classiﬁcation system
by Brooker et al. [6] is commonly used to categorize the degree
of HTO. In this classiﬁcation mechanism, ﬁve classiﬁcations are
used: grade 0 – no soft tissue calciﬁcation; grade 1 – separate small
foci of ossiﬁcation about the hip; grade 2 – ossiﬁcation projecting
from the proximal femur or pelvis with at least 1 cm between
opposing bone surfaces; grade 4 – ossiﬁcation completely bridging
the proximal femur and pelvis. Nonetheless, reports of HTO have
included other sites, such as the knee, elbow, and temporomandib-
ular joint (TMJ).
In the surgical setting, prophylaxis for HTO is regularly indi-
cated due to the considerable risk of functional impairment. The
two most common preventative modalities are radiotherapy and
indomethacin, a non-steroidal anti-inﬂammatory drug (NSAID).
In a meta-analysis of 1295 patients receiving surgery to the hip
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phylaxis against HTO, Vavken et al. demonstrated no statistically
or clinically signiﬁcant differences between arms (test for overall
effectiveness: risk ratio (RR) = 1.2; 95% CI = 0.8–1.8; p = 0.48) [7].
Both treatment modalities carry the risk of particular side effects;
for instance, indomethacin can cause peripheral edema and hyper-
tension, whereas radiotherapy may induce carcinogenesis. Vavken
et al. showed that no statistically signiﬁcant difference in treat-
ment-associated side effects between radiotherapy and indometh-
acin existed (RR = 0.79; 95% CI = 0.5–1.4; p = 0.4) [7].
For prevention of HTO, radiotherapy prevents bone repair and
consequently prevents the abnormal formation of bone. Speciﬁ-
cally, radiotherapy inhibits the differentiation of mesenchymal
stem cells to osteogenic pathways [8]. Numerous radiotherapy pre-
scription parameters, such as fractionation schedule, timing, and
dose are currently commonplace in the literature. Although a mul-
titude of prospective and retrospective cohorts, case series, and
randomized controlled trials have described the radiotherapy pre-
scription patterns in HTO, thus far there has been no formal syn-
thesis of the vast quantity of data in a meta-analysis. Further, no
evidence-based guidelines have been devised to aid the clinician
in decision-making for HTO prophylaxis with radiotherapy.
The following systematic review and meta-analysis aims to
explore pertinent issues to the prescribing radiation oncologist in
the prophylaxis of HTO: (1) what dose of radiotherapy is optimal?
(2) Should radiotherapy be prescribed postoperatively or preoper-
atively? (3) What does the evidence suggest about prophylactic
radiotherapy for recurrent versus new HTO? and (4) Is there a dif-
ference in outcomes between radiotherapy prescribed to the hip,
elbow, knee and other sites?Methods
Literature search
A literature search on Ovid Medline and Ovid OldMedline (1946
to June Week 1 2013), Embase and Embase Classic (1947 to 2013
Week 24), and the Cochrane Central Register of Controlled Trials
(May 2013) was performed. The search term ‘‘heterotopic ossiﬁca-
tion’’ was combined in various methods with the terms ‘‘radiother-
apy’’, ‘‘radiation therapy’’, ‘‘radiation prophylaxis’’, and ‘‘cancer
radiotherapy’’ to elicit relevant literature. Search results were
limited to English language human trials.Inclusion/exclusion criteria
Large (i.e. >5 site) case series, prospective and retrospective
cohort studies and randomized controlled trials were included.
For inclusion, relevant HTO outcomes needed to be stratiﬁed by
dose of radiotherapy and radiation treatment site. Cohorts were
only included if the average or median length of radiographic fol-
low-up exceeded 8 weeks. This approach is in line with other
authors, who have reported that 89% of HTO formation can be
recognized on radiography at 3 weeks [2], and all ossiﬁcation
may be appreciated 8 weeks postoperatively [9].Data collection
In data collection, each included cohort was stratiﬁed by radia-
tion dose. Collected data included: type of study, year of treatment,
treatment center location, author-reported categorical risk of
developing HTO, number of sites undergoing prophylactic radio-
therapy, type of site, type of orthopedic intervention, radiation
dose, formation of HTO prior to irradiation in the current study
protocol, time of radiotherapy (postoperative versus preoperative),percentage of sites developing HTO, Brooker grade 1 or 2 HTO, and
Brooker grade 3 or 4 HTO before and adequately after radiotherapy.Statistical analysis
Demographic information was summarized as a proportion for
categorical variables, and as a weighted mean (with a correspond-
ing standard deviation (SD), 95% conﬁdence interval (CI)), median,
and range for continuous variables. To compare primary outcomes
in patients with different socio-demographic and clinical parame-
ters from different study arms, weighted linear regression analysis
was conducted for continuous or categorical predictors. Procedure
General Linear Models (GLMs) were performed for the unbalanced
data, with the total number of treatment sites from each study
considered as a weighted variable.
The weighted mean was deﬁned as xw ¼ RiwixiRiwi , while the
weighted variance was deﬁned as S2w ¼ 1dRiwiðxi  xwÞ2, where wi
is the weight for the ith study, xi is the ith variable value, and the
divisor d is n1. The weighted variance is a measure of variability,
and it is the sum of the weighted squared distance of data value
from the mean divided by the variance divisor which is deﬁned
to be n1.
Three primary outcomes were considered in the study: the per-
centage of sites developing any type of HTO, the percentage of sites
developing Brooker grades 1 or 2 HTO, and the percentage of sites
developing Brooker grades 3 or 4 HTO. Weighted Pearson correla-
tions (r) between the mean year treated and the three primary out-
comes were also calculated and presented on bubble charts. In the
bubble charts, the size of the bubbles was related to the number of
weighted sites, with large bubbles representing a larger number of
sites. A weighted trend line was added based on the weighted
linear regression model for each outcome.
A p-value of less than 0.05 was considered to be statistically
signiﬁcant. All analyses were conducted by Statistical Analysis of
Software (SAS version 9.3 for Windows).Results
From a literature search of 528 articles, 407 articles were
excluded in title and abstract screening (Fig. 1). Of 121 articles
included in full-text screening, 60 were deemed ineligible; thus,
a total of 61 studies [9–69] spanning 85 separate study arms were
included (Fig. 1). In total, 5464 treatment sites were included.
In terms of demographic characteristics, 3015 treatment sites
(55.18%) came from patients treated in the United States, while
1762 sites were treated in Germany (32.25%) (Table 1). As deter-
mined by self-reported criteria, 1529 treatment sites (27.98%) were
deemed to be at a high risk of developing future HTO. Radiation
was prescribed mostly to the hip (n = 5336; 97.66%); other treat-
ment sites included the elbow [21,26,38,40–41,56], temporoman-
dibular joint [18,51], and knee [41,62]. A few studies reported on
whether their patient sample had any past history of HTO; of these,
280 treatment sites (5.12%) were being treated for solely recurrent
HTO, whereas 176 sites (3.22%) did not have a past history of HTO
[11,17,23–24,36,56,62]. In terms of radiation parameters, radiation
was prescribed mostly postoperatively (n = 3364; 61.57%) and over
60% at a dose of 700 cGy (n = 3331). Nonetheless, there existed a
great variability in the dose prescription of radiotherapy
(mean ± SD: 816.2 ± 2421.1 cGy; median total dose (range): 700
(500–2000); range of dose per fraction: 200–800). The median year
of treatment was 1999, which ranged from 1974 to 2007.
Regarding the distributions of primary outcomes, the percent-
age of sites developing HTO after any type of radiotherapy was,
on average, 24.8% (median: 18%; 95% CI of mean: 20.9–28.8%)
(Table 2). Similarly, the mean percentage of sites developing
29
Records identified 
through Ovid Medline 
(n = 172) 
Records screened 
(n = 528) 
Full-text articles assessed 
for eligibility 
(n = 121) 
Full-text articles excluded
(n = 60)
• Data reported on unique HTO 
conditions/definition (n=2) 
• Follow-up period not reported (n=1) 
• Follow-up < 8 weeks (n=1) 
• No clinical outcomes reported (n=1) 
• No data reported for specific joint type (n=1) 
• No data reported on a specified radiotherapy 
dosage (n=14) 
• No data reported on outcome post-
radiotherapy (n=1) 
• No radiotherapy administered (n=4) 
• No relevant outcome (n=3) 
• Not enough sites per radiation dose (n=2) 
• Outcomes for specific treatment group not 
reported (n=1) 
• Radiation administration for purposes other 
than HTO prophylaxis (n=2) 
• Data already included in synthesis from 
alternate study (n=6)
• Not in English (n=7) 
• Ineligible study design (n=5) 
• Peer-reviewed full-text article not published 
or accessible (n=8) 
• Other (n=1) 
Studies included in 
qualitative synthesis 
(n = 61) 
Studies included in 
quantitative synthesis 
(meta-analysis)
(n = 61) 
Records identified 
through Cochrane Central 
(n = 60) 
Records identified 
through Ovid Embase 
(n = 296) 
Records excluded
(n = 407)
• Not in humans (n=3) 
• Ineligible study design (n=236): 
o Responses (n=12) 
o Case reports (n=51) 
o Small case series (n=15) 
o Commentaries/ letters (n=9) 
o Models/economic analyses (n=3) 
o Guidelines (n=2) 
o Lab studies (n=5) 
o Reviews/meta-analyses/pooled
analyses (n=138) 
o Reports (n=1) 
• No post-radiotherapy incidence of HTO 
reported (n=55) 
• Follow-up median/mean < 8 weeks (n=2) 
• Duplicate inclusions (n=111) 
Fig. 1. Modiﬁed preferred reporting items for systematic reviews and meta-analyses ﬂow of information diagram for included studies.
12 Radiotherapy for Heterotopic OssiﬁcationBrooker grade 1 or 2 HTO was 22.1% (median: 17%; 95% CI of mean:
18.1–26.2%), whereas the mean percentage of sites developing
Brooker grade 3 or 4 HTO was 4.1% (median: 2%; 95% CI of mean:
2.9–5.3%).
The association between the percentage of sites developing HTO
and the prescribed dose of radiation was investigated after adjust-
ing for radiation site (i.e. hip, knee, TMJ, elbow) as a confounding
factor. This particular analysis was completed on all included treat-
ment sites, irrespective of prior history of HTO and preoperative
versus postoperative status. Overall, it was found that there was
no statistically signiﬁcant relationship between the percentage ofsites developing HTO and radiation dose (coefﬁcient = 0.011;
SE = 0.007; p = 0.095).
We next examined the impact of preoperative versus postoper-
ative status on the percentage of sites developing HTO. It was
found that, after adjusting for radiation site as a confounding fac-
tor, there was no statistically signiﬁcant relationship between pre-
operative/postoperative status and the percentage of sites
developing HTO (coefﬁcient = 6.93; SE = 4.20; p = 0.10), as well as
Brooker grade 3 or 4 HTO (coefﬁcient = 2.07; SE = 1.25; p = 0.10).
Conversely, sites which were prescribed radiotherapy postopera-
tively had a signiﬁcantly higher percentage of sites developing
M. Popovic et al. / Radiotherapy and Oncology 113 (2014) 10–17 13Brooker grade 1 or 2 HTO, relative to preoperatively prescribed
sites (coefﬁcient = 8.19; SE = 4.10; p = 0.0499). The confounding
factor of radiation site was not signiﬁcantly related to any
outcome.
It was also possible that past medical history of patients may
have inﬂuenced results, especially if history was signiﬁcant forTable 1
Demographic information for the included sample.
Type of study
Retrospective 2061 (37.72%)
Randomized controlled trial 1253 (22.93%)
Prospective 1012 (18.52%)
Unknown 695 (12.72%)
N/A 443 (8.11%)
Treatment center
United States 3015 (55.18%)
Germany 1762 (32.25%)
Italy 279 (5.11%)
Greece 89 (1.63%)
Belgium 83 (1.52%)
France 54 (0.99%)
Canada 47 (0.86%)
Switzerland 47 (0.86%)
The Netherlands 43 (0.79%)
South Korea 19 (0.35%)
United Kingdom 14 (0.26%)
Australia 12 (0.22%)
Risk of developing heterotopic ossiﬁcation
High risk 1529 (27.98%)
At risk 291 (5.33%)
Mixed risk 194 (3.55%)
Standard risk 47 (0.86%)
Unknown 3403 (62.28%)
Site of radiation
Hip 5336 (97.66%)
Elbow 87 (1.59%)
Temporomandibular joint 22 (0.40%)
Knee 19 (0.35%)
New heterotopic ossiﬁcation or recurrence of old
ossiﬁcation
Recurrence 280 (5.12%)
New 176 (3.22%)
Mixed 1830 (33.49%)
Unknown 3178 (58.16%)
Radiation prescribed preoperatively or postoperatively
Postoperatively 3364 (61.57%)
Preoperatively 2072 (37.92%)
Mixed 28 (0.51%)
Radiation dose (cGy)
500 165 (3.02%)
550 19 (0.35%)
600 321 (5.87%)
700 3331 (60.96%)
750 182 (3.33%)
800 286 (5.23%)
990 77 (1.41%)
1000 613 (11.22%)
1200 120 (2.20%)
1500 13 (0.24%)
1750 199 (3.64%)
2000 138 (2.53%)
Radiation dose (cGy)
n 85
Mean ± SD 816.2 ± 2421.1
95% conﬁdence interval (CI) of mean 751.0–881.3
Median (range) 700 (500–2000)
Mean year treated
n 77
Mean ± SD 1996.2 ± 54.8
95% conﬁdence interval (CI) of mean 1994.7–1997.7
Median (range) 1999 (1974–
2007)
Note: All values indicate number of treatment sites treated by radiotherapy rather
than number of patients.previous HTO. As such, an analysis was conducted to determine
whether the incidence of HTO was different in sites undertaking
prophylaxis for recurrence rather than HTO for the ﬁrst time.
Adjusted for radiation site, there was a statistically signiﬁcant dif-
ference between new and recurrent cohorts in the percentage of
sites developing HTO (coefﬁcient = 32.14; SE = 15.31; p = 0.041)
as well as the percentage of sites developing Brooker grade 1 or
2 HTO (coefﬁcient = 37.21; SE = 14.80; p = 0.016). The analysis for
Brooker grade 3 or 4 HTO was statistically insigniﬁcant (coefﬁ-
cient = 2.34; SE = 3.05; p = 0.45). Further, the confounding factor
of radiation site was not signiﬁcantly related to any outcome.
In ascertaining the development of HTO as a result of radiother-
apy, it was also critical to document the efﬁcacy of prescription
patterns over the course of many years. Accordingly, a time trend
analysis was performed, adjusting for site of radiation. A statisti-
cally signiﬁcant trend was found in which the percentage of sites
developing HTO (coefﬁcient = 0.85; SE = 0.32; p = 0.009) and devel-
oping Brooker grade 1/2 HTO (coefﬁcient = 1.08; SE = 0.35;
p = 0.003) decreased signiﬁcantly over time. However, there was
no statistically signiﬁcant trend found in analyzing the incidence
of Brooker grade 3/4 HTO (coefﬁcient = 0.15; SE = 0.12; p = 0.22).
Once again, the confounding factor of radiation site did not inﬂu-
ence any outcome. The data were then graphically presented in a
bubble chart, with the x axis represented as the mean year treated
and the y axis as each primary outcome. Upon computing the
weighted Pearson correlation coefﬁcient, it was discovered that a
moderate, negative relationship existed between the percentage
of sites developing HTO and mean year of treatment (r = 0.32;
p = 0.007; Fig. 2a). When this analysis was subdivided into Brooker
grade groups, a similarly moderate, downward sloping relationship
was found for Brooker grades 1/2 (r = 0.39; p = 0.002; Fig. 2b),
whereas no statistically signiﬁcant relationship was discovered
for Brooker grades 3/4 (r = 0.16; p = 0.21; Fig. 2c).
A time trend analysis was also completed for radiation dose
(Fig. 3), which demonstrated a highly signiﬁcant downward slop-
ing relationship between the prescribed dose and the mean year
of treatment (r = 0.53; p < 0.0001).Discussion
In the heterotopic ossiﬁcation setting, radiation has been used
consistently as a prophylaxis [7]. Over the years, evidence-based
guidelines aiming to standardize radiotherapy regimens for these
patients have not been devised, leading to a wide variability in
the prescription patterns of radiation oncologists. This systematicTable 2
Distribution of heterotopic ossiﬁcation incidence following any prophylactic radio-
therapy regimen.
Percentage of sites developing heterotopic ossiﬁcation
n 79
Mean ± SD 24.8 ± 146.1
95% conﬁdence interval (CI) of mean 20.9–28.8
Median (range) 18(0–100)
Percentage of sites developing Brooker grade 1/2 heterotopic
ossiﬁcation
n 70
Mean ± SD 22.1 ± 137.4
95% conﬁdence interval (CI) of mean 18.1–26.2
Median (range) 17(0–92)
Percentage of sites developing Brooker grade 3/4 heterotopic
ossiﬁcation
n 69
Mean ± SD 4.1 ± 41.7
95% conﬁdence interval (CI) of mean 2.9–5.3
Median (range) 2(0–38)
Fig. 2a. Bubble chart demonstrating the distribution of the percentage of sites developing heterotopic ossiﬁcation within individual cohorts as a function of mean year
treated.
Fig. 2b. Brooker grades 1 or 2 heterotopic ossiﬁcation.
14 Radiotherapy for Heterotopic Ossiﬁcationreview and meta-analysis has examined critical areas in this
respect, especially in terms of appropriate dosing, preoperative
versus postoperative prophylaxis, as well as differences in efﬁcacy
in various treatment sites and in patients with dissimilar medical
histories.
Given the large number of treatment sites involved (n = 5464),
it is the hope of the authors that these results will be generalizable
and useful to the practicing radiation oncologist. Nonetheless, it is
important to emphasize that the vast majority of included sites
(97.7%) were exclusively in the hip region. Although there was
no statistically signiﬁcant difference in outcomes between various
treatment sites, these results should be interpreted with caution,
as only 87, 22, and 19 sites were the elbow [21,26,38,40–41,56],
temporomandibular joint [18,51], and knee [41,62], respectively.
As such, future research in diverse sites of HTO prophylaxis is
encouraged.
In terms of dosing, 700 cGy has been by far the most common
dose prescribed, especially in recent years (Fig. 3). This ﬁnding is
in line with numerous included studies that have supported theefﬁcacy of such a regimen [14–15,17,21,23–24,26]. When radiation
dose was compared to the incidence of HTO, a positive relationship
was found between the predictor and outcome (weighted coefﬁ-
cient: 0.01). However, this was statistically insigniﬁcant even with
such high statistical power (p = 0.1). Given that higher doses of
radiotherapy readily require more protracted fractionation sched-
ules [70], our analysis conﬁrms that low doses, such as 700 cGy,
provide an efﬁcacious prophylaxis while minimizing patient
burden.
Although postoperative radiotherapy has traditionally been the
gold standard for HTO prophylaxis, more recently the role of pre-
operative administration [31–32,34,36,49–50,53,59–60,65] has
been explored. In our analysis, most sites were indeed prescribed
radiotherapy postoperatively (n = 3364; 61.6%), with a smaller pro-
portion being prescribed preoperative prophylaxis (n = 2072;
37.9%). For all three primary outcomes, p-values achieved or were
close to achieving statistical signiﬁcance. The only statistically
signiﬁcant ﬁnding that was discovered was in the proportion of
sites developing Brooker grades 1/2 HTO: the proportion was
Fig. 2c. Brooker grades 3 or 4 heterotopic ossiﬁcation.
Fig. 3. Bubble chart visualizing the distribution of radiation dose prescription patterns across all sites in relation to the mean year of treatment.
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ative to preoperative treatment (p = 0.0499). Although reaching
statistical signiﬁcance, it is unclear how clinically relevant these
results may be, given the large sample sizes involved. Speciﬁcally,
it is uncertain whether patient outcomes would be improved
substantially by diminishing the ﬂexibility of the radiotherapy cen-
ter to prescribe prophylaxis either pre or postoperatively. Future
research investigating this issue is warranted.
As Fig. 3 suggests, there has not been a dramatic shift in radio-
therapy prescription patterns over the last twenty years. Neverthe-
less, the percentage of sites developing heterotopic ossiﬁcation
after prophylaxis with radiotherapy has consistently diminished
over time (r = 0.32, p = 0.007). In the present day, it is common
for the incidence of HTO to be anywhere between 0% and 30% of
sites (Fig. 2a). This is in contrast to rates of 0–80% of sites observed
in the 1980s (Fig. 2a). Of the sites which develop HTO today, most
cases will be Brooker grade 1 or 2 HTO and thus less clinically
signiﬁcant (Fig. 2b). Ultimately, the sustained reduction in HTOincidence over time may be more a result of the large surgical
advances in this setting, as there is no evidence to support a rela-
tionship between modiﬁed radiotherapy parameters and drasti-
cally improved clinical outcomes. Future studies should aim to
examine the role of changing surgical technique in the improve-
ment of outcomes over time in this setting.
There are limitations to the methodology employed in the pres-
ent study. First, all data were analyzed at the level of the cohort as
opposed to the patient; although all analyses were weighted by the
number of treatment sites receiving radiotherapy per cohort, the
relationships that may hold true at the cohort level may not neces-
sarily be true at the patient level. Further, as a means of increasing
statistical power, especially in treatment sites that are traditionally
underreported in the literature, the results of different study
designs were pooled. As well, the total dose was used in all analy-
ses as opposed to the biologically effective dose because certain
included trials did not disclose the dose fractionation schedules
that were employed.
16 Radiotherapy for Heterotopic OssiﬁcationIn closing, this meta-analysis has served to consolidate the vast
research that has accumulated in the HTO setting over the last
40 years. Low dose radiotherapy is a safe and efﬁcacious method
of preventing HTO formation in sites such as the hip, elbow, knee,
and temporomandibular joint.Conﬂicts of interest
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